Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing⁻Remitting Multiple Sclerosis.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
24 01 2019
Historique:
received: 14 12 2018
revised: 16 01 2019
accepted: 22 01 2019
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 27 1 2019
Statut: epublish

Résumé

To better understand the pathophysiological differences between secondary progressive multiple sclerosis (SPMS) and relapsing-remitting multiple sclerosis (RRMS), and to identify potential biomarkers of disease progression, we applied high-resolution mass spectrometry (HRMS) to investigate the metabolome of cerebrospinal fluid (CSF). The biochemical differences were determined using partial least squares discriminant analysis (PLS-DA) and connected to biochemical pathways as well as associated to clinical and radiological measures. Tryptophan metabolism was significantly altered, with perturbed levels of kynurenate, 5-hydroxytryptophan, 5-hydroxyindoleacetate, and

Identifiants

pubmed: 30678351
pii: cells8020084
doi: 10.3390/cells8020084
pmc: PMC6406712
pii:
doi:

Substances chimiques

Pyrimidines 0
Serotonin 333DO1RDJY
Kynurenine 343-65-7
Phenylalanine 47E5O17Y3R
Tryptophan 8DUH1N11BX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

OMICS. 2016 Nov;20(11):645-661
pubmed: 27828769
J Immunol Res. 2015;2015:354957
pubmed: 25961058
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
J Proteome Res. 2015 Aug 7;14(8):3322-35
pubmed: 26088811
Brain Topogr. 2016 Mar;29(2):296-307
pubmed: 26440606
Acta Neurol Scand. 2014 Aug;130(2):81-9
pubmed: 24571714
Sci Rep. 2017 Feb 03;7:41473
pubmed: 28155867
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Neural Transm (Vienna). 2007;114(8):1011-5
pubmed: 17393066
Trends Mol Med. 2013 Jun;19(6):336-44
pubmed: 23562344
Curr Pharm Biotechnol. 2011 Jul;12(7):1016-25
pubmed: 21466459
Nat Commun. 2018 Jun 19;9(1):2397
pubmed: 29921915
PLoS One. 2017 Jul 26;12(7):e0181758
pubmed: 28746356
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321
pubmed: 28180139
Nucleic Acids Res. 2015 Jul 1;43(W1):W251-7
pubmed: 25897128
Mol Cell Proteomics. 2014 Jan;13(1):348-59
pubmed: 24176773
NMR Biomed. 2010 Feb;23(2):123-32
pubmed: 19691132
Lancet Neurol. 2015 Feb;14(2):208-23
pubmed: 25772899
Nat Biotechnol. 2012 Oct;30(10):918-20
pubmed: 23051804
J Proteome Res. 2013 Apr 5;12(4):1628-44
pubmed: 23391308
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978801
Metabolomics. 2017;13(7):79
pubmed: 28596718
Int J Epidemiol. 2013 Aug;42(4):1111-9
pubmed: 23838602
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Nat Neurosci. 2014 Jan;17(1):121-30
pubmed: 24270187
Neurosci Lett. 2002 Oct 4;331(1):63-5
pubmed: 12359324
Neurol Neuroimmunol Neuroinflamm. 2015 Dec 24;3(1):e185
pubmed: 26740964
Int J Mol Sci. 2015 Aug 06;16(8):18270-82
pubmed: 26287161
Mult Scler. 2014 Sep;20(10):1396-400
pubmed: 24468817
Neurochem Int. 2018 Jan;112:1-4
pubmed: 29080803
Curr Med Chem. 2016;23(14):1408-31
pubmed: 27063261
Acta Neuropathol Commun. 2017 Dec 06;5(1):95
pubmed: 29208041
Front Physiol. 2015 Dec 17;6:383
pubmed: 26733877
Mult Scler. 2016 Apr;22(4):451-60
pubmed: 26754801
Drugs. 2014 Apr;74(6):659-74
pubmed: 24740824
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025
pubmed: 29774057
Front Hum Neurosci. 2018 Jun 04;12:226
pubmed: 29915533
Pharmacol Rep. 2017 Aug;69(4):702-708
pubmed: 28550802
Mult Scler. 2016 Jan;22(1):112-6
pubmed: 26014604
Physiol Genomics. 2017 Sep 1;49(9):447-461
pubmed: 28754822
BMJ. 2016 Aug 22;354:i3518
pubmed: 27549763
Mult Scler. 2018 Aug;24(9):1144-1150
pubmed: 29117778
Theranostics. 2018 Aug 07;8(16):4477-4490
pubmed: 30214633
Cell Rep. 2018 Apr 24;23(4):1099-1111
pubmed: 29694888
PLoS One. 2007 Jul 04;2(7):e595
pubmed: 17611627
PLoS One. 2015 Apr 09;10(4):e0117705
pubmed: 25856304
J Neurosci. 2015 Nov 11;35(45):15170-86
pubmed: 26558787
Acta Neurol Scand. 2005 Aug;112(2):93-6
pubmed: 16008534
J Neurochem. 2009 Jan;108(1):158-64
pubmed: 19014375
Ann Clin Transl Neurol. 2018 Oct 30;6(1):33-45
pubmed: 30656182
Int J Biochem Cell Biol. 2017 Dec;93:148-155
pubmed: 28720279
Eur J Nucl Med Mol Imaging. 2014 May;41(5):827-35
pubmed: 24562640
Nat Rev Drug Discov. 2013 Jan;12(1):64-82
pubmed: 23237916
Ann Clin Transl Neurol. 2018 Sep 27;5(10):1211-1221
pubmed: 30349856

Auteurs

Stephanie Herman (S)

Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden. Stephanie.herman@medsci.uu.se.
Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden. Stephanie.herman@medsci.uu.se.

Torbjörn Åkerfeldt (T)

Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden. Torbjorn.akerfeldt@akademiska.se.

Ola Spjuth (O)

Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden. Ola.spjuth@farmbio.uu.se.

Joachim Burman (J)

Department of Neuroscience, Uppsala University, 751 85 Uppsala, Sweden. Joachim.burman@neuro.uu.se.

Kim Kultima (K)

Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden. Kim.kultima@medsci.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH